Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254431 | 0.78 | L3MBTL1 (0.33) | IDO1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL9460799 | 0.78 | EPHX1 (0.38) | CYP3A4CYP1A2CYP2D6TSHRGAA | |
| SCHEMBL9460882 | 0.78 | EPHX1 (0.38) | CYP3A4CYP1A2CYP2D6TSHRGAA | |
| SCHEMBL3909948 | 0.78 | GAA (0.41) | CYP3A4CYP1A2CYP2D6GAAL3MBTL1 | |
| SCHEMBL9460794 | 0.78 | EPHX1 (0.38) | CYP3A4CYP1A2CYP2D6TSHRGAA | |
| SCHEMBL2202292 | 0.74 | GAA (0.37) | IDO1CYP2D6TSHRGAAL3MBTL1 | |
| SCHEMBL2677106 | 0.70 | IDO1 (0.50) | DPP4F2IDO1OPRM1OPRD1 | |
| SCHEMBL11885874 | 0.70 | IDO1 (0.50) | DPP4F2IDO1OPRM1OPRD1 | |
| SCHEMBL20721292 | 0.70 | IDO1 (0.55) | DPP4F2IDO1OPRM1OPRD1 | |
| SCHEMBL2677194 | 0.70 | IDO1 (0.55) | DPP4F2IDO1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | claimed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | claimed |
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | ITGA4, ITGB4, ITGB7 | DPP4 912/4885F2 1258/4885IDO1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.